Formed in July 2007 and incorporated in October 2007, it was founded by approximately 100 parents of young children with neuroblastoma who were treated at Memorial Sloan Kettering Cancer Center (MSKCC).
Even with aggressive therapy, stage IV neuroblastoma carries a poor prognosis, with a three-year survival rate of 30–40%.
Scientific advances have allowed the development of individualized treatments, with techniques such as immunotherapy being targeted to specific kinds of cancer.
In addition to surgery, chemotherapy and radiation, many neuroblastoma patients at MSKCC were treated with a murine (mouse-derived) monoclonal antibody called 3F8.
[8] In March 2013, the Band of Parents led a group of nonprofit organizations in providing a $2 million grant to MSKCC to fund the development of a bispecific monoclonal antibody targeting neuroblastoma.